United States Health

Zepp Health (NYSE:ZEPP) reported second-quarter 2026 revenue of US$63.5 million, up 6.9% year over year, as the company recorded higher gross margins and expanded product activity.

Evotec (NASDAQ:EVO) and Plectonic Biotech have entered a research collaboration to evaluate a T-cell-engaging immunotherapy concept for solid tumors using their respective biotechnology platforms.

Biomerica (NASDAQ:BMRA) reported fiscal 2026 revenue of approximately $4.50 million, down from $5.30 million in fiscal 2025, while net loss improved to $3.8 million.

Alumis (NASDAQ:ALMS) reported Phase 2b LUMUS trial results for oral TYK2 inhibitor envudeucitinib in moderate-to-severe systemic lupus erythematosus, with the overall study population not meeting the primary endpoint.

Emergent BioSolutions (NYSE:EBS) received a contract modification valued at approximately $24 million from BARDA to supply CYFENDUS anthrax vaccine for U.S. government preparedness programs.

Kazia Therapeutics (NASDAQ:KZIA) reported preclinical data showing its PI3K/mTOR inhibitor paxalisib reduced tumor burden by 52% in an MSS/pMMR colorectal cancer model.

Kazia Therapeutics (NASDAQ:KZIA) reported preclinical results showing its PI3K/mTOR inhibitor paxalisib produced antitumor activity when combined with standard therapies in HR+/HER2- breast cancer models.

RedHill Biopharma (NASDAQ:RDHL) acquired exclusive global commercialization rights to Rebyota and exclusive U.S. rights to Clenpiq from Ferring Pharmaceuticals in a transaction focused on expanding its gastrointestinal business.

Adicet Bio (NASDAQ:ACET) completed the last patient visit for the planned Phase 1 safety and efficacy analysis of prulacabtagene leucel (prula-cel) in patients with systemic lupus erythematosus with or without lupus nephritis.

AstraZeneca (NASDAQ:AZN) completed its exclusive license agreement with Dizal Pharmaceutical for worldwide rights to develop and commercialize ZEGFROVY (sunvozertinib), an oral EGFR inhibitor for patients with lung cancer.

MiniMed (NASDAQ:MMED) reported first quarter fiscal 2027 net sales of $843 million, increasing 16.6% year over year on a reported basis and 15.8% organically.

Novartis (NYSE:NVS) reported positive Phase 3 REMODEL-1 and REMODEL-2 trial results showing remibrutinib reduced annualized relapse rates compared with teriflunomide in adults with relapsing multiple sclerosis.